ARGONEX PHARMACEUTICALS has a total of 11 patent applications. Its first patent ever was published in 2000. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and EPO (European Patent Office). Its main competitors in its focus markets biotechnology and pharmaceuticals are ROSKILDE MEDICAL COMPANY LTD R, HARBIN BOAO BIOLOG MEDICAL TECHNOLOGY DEV CO LTD and AGRICURA LABOR LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 4 | |
#2 | Australia | 3 | |
#3 | EPO (European Patent Office) | 3 | |
#4 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Hunt Donald F | 7 |
#2 | White Forest M | 4 |
#3 | Ross Mark M | 4 |
#4 | Flyer David | 4 |
#5 | Ross Mark | 4 |
#6 | White Forest | 3 |
#7 | Shabanowitz Jeffrey | 3 |
#8 | Ramakrishna Venky | 2 |
#9 | Philip Ramila | 2 |
#10 | Slingluff Craig L | 2 |
Publication | Filing date | Title |
---|---|---|
AU2740602A | Mhc class i associated peptides for prevention and treatment of tuberculosis | |
EP1356048A2 | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
AU7549001A | Mhc peptides over-expressed on prostate cancer cells and methods of use | |
AU1440601A | Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma |